Data from EMC - Curated by EPG Health - Last updated 18 August 2016


Colomycin is indicated in the treatment of the following infections where sensitivity testing suggests that they are caused by susceptible bacteria:

- Treatment by inhalation of Pseudomonas aeruginosa lung infection in patients with cystic fibrosis (CF).

- Intravenous administration for the treatment of some serious infections caused by Gram-negative bacteria, including those of the lower respiratory tract and urinary tract, when more commonly used systemic antibacterial agents may be contra-indicated or may be ineffective because of bacterial resistance.


Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Related Content

More information

Category Value
Orphan designation No
Type POM
Marketing authorisation holder Forest Laboratories UK Limited